Literature DB >> 27807235

Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer.

Anna-Janina Behrens1, David J Harvey1, Emilia Milne1, Albert Cupo2, Abhinav Kumar1, Nicole Zitzmann1, Weston B Struwe1, John P Moore2, Max Crispin3,4.   

Abstract

The formation of a correctly folded and natively glycosylated HIV-1 viral spike is dependent on protease cleavage of the gp160 precursor protein in the Golgi apparatus. Cleavage induces a compact structure which not only renders the spike capable of fusion but also limits further maturation of its extensive glycosylation. The redirection of the glycosylation pathway to preserve underprocessed oligomannose-type glycans is an important feature in immunogen design, as glycans contribute to or influence the epitopes of numerous broadly neutralizing antibodies. Here we present a quantitative site-specific analysis of a recombinant, trimeric mimic of the native HIV-1 viral spike (BG505 SOSIP.664) compared to the corresponding uncleaved pseudotrimer and the matched gp120 monomer. We present a detailed molecular map of a trimer-associated glycan remodeling that forms a localized subdomain of the native mannose patch. The formation of native trimers is a critical design feature in shaping the glycan epitopes presented on recombinant vaccine candidates. IMPORTANCE: The envelope spike of human immunodeficiency virus type 1 (HIV-1) is a target for antibody-based neutralization. For some patients infected with HIV-1, highly potent antibodies have been isolated that can neutralize a wide range of circulating viruses. It is a goal of HIV-1 vaccine research to elicit these antibodies by immunization with recombinant mimics of the viral spike. These antibodies have evolved to recognize the dense array of glycans that coat the surface of the viral molecule. We show how the structure of these glycans is shaped by steric constraints imposed upon them by the native folding of the viral spike. This information is important in guiding the development of vaccine candidates.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  furin; glycan; glycosylation; human immunodeficiency virus; neutralizing antibodies; oligosaccharides; structure; vaccines

Mesh:

Substances:

Year:  2017        PMID: 27807235      PMCID: PMC5215339          DOI: 10.1128/JVI.01894-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  78 in total

1.  A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.

Authors:  J M Binley; R W Sanders; B Clas; N Schuelke; A Master; Y Guo; F Kajumo; D J Anselma; P J Maddon; W C Olson; J P Moore
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

3.  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Authors:  Jean-Philippe Julien; Jeong Hyun Lee; Albert Cupo; Charles D Murin; Ronald Derking; Simon Hoffenberg; Michael J Caulfield; C Richter King; Andre J Marozsan; Per Johan Klasse; Rogier W Sanders; John P Moore; Ian A Wilson; Andrew B Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-20       Impact factor: 11.205

4.  The convertases furin and PC1 can both cleave the human immunodeficiency virus (HIV)-1 envelope glycoprotein gp160 into gp120 (HIV-1 SU) and gp41 (HIV-I TM).

Authors:  E Decroly; M Vandenbranden; J M Ruysschaert; J Cogniaux; G S Jacob; S C Howard; G Marshall; A Kompelli; A Basak; F Jean
Journal:  J Biol Chem       Date:  1994-04-22       Impact factor: 5.157

5.  Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.

Authors:  Marie Pancera; Syed Shahzad-Ul-Hussan; Nicole A Doria-Rose; Jason S McLellan; Robert T Bailer; Kaifan Dai; Sandra Loesgen; Mark K Louder; Ryan P Staupe; Yongping Yang; Baoshan Zhang; Robert Parks; Joshua Eudailey; Krissey E Lloyd; Julie Blinn; S Munir Alam; Barton F Haynes; Mohammed N Amin; Lai-Xi Wang; Dennis R Burton; Wayne C Koff; Gary J Nabel; John R Mascola; Carole A Bewley; Peter D Kwong
Journal:  Nat Struct Mol Biol       Date:  2013-05-26       Impact factor: 15.369

6.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

7.  Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation.

Authors:  Rajesh P Ringe; Rogier W Sanders; Anila Yasmeen; Helen J Kim; Jeong Hyun Lee; Albert Cupo; Jacob Korzun; Ronald Derking; Thijs van Montfort; Jean-Philippe Julien; Ian A Wilson; Per Johan Klasse; Andrew B Ward; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

8.  Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope.

Authors:  Laura K Pritchard; David J Harvey; Camille Bonomelli; Max Crispin; Katie J Doores
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

9.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

10.  Deletion of the highly conserved N-glycan at Asn260 of HIV-1 gp120 affects folding and lysosomal degradation of gp120, and results in loss of viral infectivity.

Authors:  Leen Mathys; Katrien O François; Matthias Quandte; Ineke Braakman; Jan Balzarini
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

View more
  40 in total

Review 1.  Glycomics and glycoproteomics of viruses: Mass spectrometry applications and insights toward structure-function relationships.

Authors:  John F Cipollo; Lisa M Parsons
Journal:  Mass Spectrom Rev       Date:  2020-04-29       Impact factor: 10.946

2.  Global N-Glycan Site Occupancy of HIV-1 gp120 by Metabolic Engineering and High-Resolution Intact Mass Spectrometry.

Authors:  Weston B Struwe; Alexandra Stuckmann; Anna-Janina Behrens; Kevin Pagel; Max Crispin
Journal:  ACS Chem Biol       Date:  2017-01-09       Impact factor: 5.100

3.  Structure and Immune Recognition of the HIV Glycan Shield.

Authors:  Max Crispin; Andrew B Ward; Ian A Wilson
Journal:  Annu Rev Biophys       Date:  2018-03-29       Impact factor: 12.981

Review 4.  Structural principles controlling HIV envelope glycosylation.

Authors:  Anna-Janina Behrens; Max Crispin
Journal:  Curr Opin Struct Biol       Date:  2017-03-29       Impact factor: 6.809

Review 5.  Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1.

Authors:  Anna-Janina Behrens; Weston B Struwe; Max Crispin
Journal:  Expert Rev Proteomics       Date:  2017-09-14       Impact factor: 3.940

Review 6.  Harnessing post-translational modifications for next-generation HIV immunogens.

Authors:  Joel D Allen; Rogier W Sanders; Katie J Doores; Max Crispin
Journal:  Biochem Soc Trans       Date:  2018-05-21       Impact factor: 5.407

7.  Metabolic labeling of HIV-1 envelope glycoprotein gp120 to elucidate the effect of gp120 glycosylation on antigen uptake.

Authors:  Lina Sun; Mayumi Ishihara; Dustin R Middleton; Michael Tiemeyer; Fikri Y Avci
Journal:  J Biol Chem       Date:  2018-08-16       Impact factor: 5.157

8.  Human Immunodeficiency Virus and Simian Immunodeficiency Virus Maintain High Levels of Infectivity in the Complete Absence of Mucin-Type O-Glycosylation.

Authors:  James M Termini; Elizabeth S Church; Zachary A Silver; Stuart M Haslam; Anne Dell; Ronald C Desrosiers
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

9.  Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.

Authors:  Eden P Go; Haitao Ding; Shijian Zhang; Rajesh P Ringe; Nathan Nicely; David Hua; Robert T Steinbock; Michael Golabek; James Alin; S Munir Alam; Albert Cupo; Barton F Haynes; John C Kappes; John P Moore; Joseph G Sodroski; Heather Desaire
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

10.  Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.

Authors:  Rajesh P Ringe; Pavel Pugach; Christopher A Cottrell; Celia C LaBranche; Gemma E Seabright; Thomas J Ketas; Gabriel Ozorowski; Sonu Kumar; Anna Schorcht; Marit J van Gils; Max Crispin; David C Montefiori; Ian A Wilson; Andrew B Ward; Rogier W Sanders; P J Klasse; John P Moore
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.